Typherix

GlaxoSmithKline
  • Indications and Usage

    • Active immunisation against typhoid fever.
  • Dosage and Administration

    For intramuscular (i.m.) injection.

    Adults and children (2 years and older):

    • 0.5 ml (25 micrograms Vi polysaccharide of Salmonella typhi Ty2 strain) at least 2 weeks prior to risk of exposure to typhoid fever. Subjects who remain at risk of typhoid fever should be revaccinated using a single dose of vaccine with an interval of not more than 3 years.
  • Dosage Forms and Strengths

    1 single dose prefilled syringe (0.5 mL)

  • Contraindications

    • Hypersensitivity to any component of the vaccine.
    • Postpone in acute severe febrile illness.
  • Warnings and Precaution

    • Appropriate medical treatment and supervision should always be readily available in cases of a rare anaphylactic reaction following administration of the vaccine.
    • Bleeding may occur following intramuscular injection to subjects with thrombocytopenia or bleeding disorders and firm pressure should be applied to the site (without rubbing) for at least two minutes for these subjects.
    • Patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate response may not be achieved.
    • Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.
  • Adverse Reactions

    • Reactions at the injection site, including soreness, redness and swelling
    • headache
    • nausea
    • itching
    • fever
    • general aches
    • malaise
    • urticaria
    • anaphylaxis
  • Use in Specific Populations

    • For pregnant and lactating, Typherix should only be used when there is high risk of infection.